// App-Quantinova.ai

1621 : Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 1830 Study (CRUK/08/012)

Researchers

Presenter

  • Kirit M Ardeshna

Principal Investigators

  • Peter Hoskin

  • Paul Smith

  • Nicholas Chadwick

  • Nivette Braganca

  • Wailup Wong

  • Irfan Kayani

  • Bal Sanghera

  • Patricia Díez

  • Helen Lucraft

  • Andrew Jack

  • Christopher J McNamara

  • George Mikhaeel

  • Scott Marshall

  • Ruth Pettengell

  • Robert E. Marcus

  • Anton Kruger

  • David C Linch

Medical Centers

  • Haematological Medicine, Kings College Hospital, London, United Kingdom

  • Infection and Immunity Division of Clinical Sciences,St. Georges University of London, London, United Kingdom

  • NCRI, London, United Kingdom

  • Department of Haematology, UCL Cancer Institute, London, United Kingdom

  • Cancer Research UK & The Department of Haematology, The Royal Free Hospital, London, United Kingdom

  • St James Institute of Oncology, Leeds, United Kingdom

  • Kings College London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Neutropenia

  • Peripheral neuropathy

  • Venous thrombosis

  • Mucositis

  • Lymphomas

Biomarkers

  • Tissue transglutaminase

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • procarbazine

  • Prednisolone

  • dacarbazine Intravenous

  • Vinblastine

  • Vincristine

  • Adriamycin injection

  • Etoposide

  • Etoposide phosphate

  • Bleomycin

Outcome

  • N/A

Study Design

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved